HIMS Tumbles 3.77% on $1.36 Billion Volume, Ranking 52nd in Market Activity Amid Regulatory Scrutiny and Shifting Business Model

On August 11, 2025, Hims & Hers Health (HIMS) closed down 3.77% with a trading volume of $1.36 billion, ranking 52nd in market activity. The decline followed the company’s disclosure of reduced revenue per order for its compounded GLP-1 weight-loss medications, a key component of its business model. The adjustment came amid a broader shift in regulatory scrutiny over mass compounding practices, forcing Hims to pivot toward personalized, smaller-dose formulations. This strategic pivot has led to a 7% sequential drop in second-quarter revenue to $545 million, with GLP-1 drug sales falling to $190 million from $230 million in the prior quarter.

The stock’s volatility reflects ongoing legal and operational challenges. A terminated partnership with Novo Nordisk, the maker of Wegovy, has raised questions about Hims’ compliance practices. Novo publicly criticized the company for “deceptive promotion” of unauthorized drug versions, leading to a 34% single-day drop in Hims’ shares when the collaboration ended. This has sparked securities class action lawsuits alleging misleading statements about the partnership and subscriber metrics. Hims’ revenue per subscriber also declined to $74 from $84, attributed to reduced GLP-1 user retention.

The company’s business model faces structural headwinds as the FDA restricts mass compounding of weight-loss drugs. Hims’ shift to personalized formulations has not yet offset declining demand, and legal uncertainties linger. Analysts highlight that the combination of revenue declines, regulatory constraints, and litigation risks has eroded investor confidence. The stock’s recent performance underscores the sector’s sensitivity to both regulatory and market dynamics.

A strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the role of liquidity concentration in short-term gains, particularly in volatile markets where high-volume stocks like Hims may experience amplified price movements due to investor behavior and macroeconomic shifts.